These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21426886)

  • 1. Education for dialysis patients lowers long-term phosphate levels and maintains health-related quality of life.
    Gardulf A; Pålsson M; Nicolay U;
    Clin Nephrol; 2011 Apr; 75(4):319-27. PubMed ID: 21426886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population.
    Reddy V; Symes F; Sethi N; Scally AJ; Scott J; Mumtaz R; Stoves J
    J Ren Nutr; 2009 Jul; 19(4):314-20. PubMed ID: 19539185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).
    Biggar P; Ketteler M
    Expert Opin Pharmacother; 2010 Nov; 11(16):2739-50. PubMed ID: 20977406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
    Yin J; Yin J; Lian R; Li P; Zheng J
    BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F
    G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?
    Cozzolino M; Mazzaferro S; Brandenburg V
    Nephrol Dial Transplant; 2011 Feb; 26(2):402-7. PubMed ID: 21079194
    [No Abstract]   [Full Text] [Related]  

  • 8. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.
    Sigrist MK; Chiarelli G; Lim L; Levin A
    J Ren Care; 2009 Mar; 35 Suppl 1():71-8. PubMed ID: 19222735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of educational interventions with dialysis patient].
    Parmier M; Gourieux B; Krummel T; Bazin-Kara D; Dory A; Hannedouche T
    Nephrol Ther; 2016 Dec; 12(7):516-524. PubMed ID: 27776970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intensified diet education on serum phosphorus and knowledge of pediatric peritoneal dialysis patients.
    Abercrombie EL; Greenbaum LA; Baxter DH; Hopkins B
    J Ren Nutr; 2010 May; 20(3):193-8. PubMed ID: 20303791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
    Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
    J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice.
    Toussaint ND; Pedagogos E; Beavis J; Becker GJ; Polkinghorne KR; Kerr PG
    Nephrol Dial Transplant; 2011 Apr; 26(4):1319-26. PubMed ID: 20935019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of nurse-led education on haemodialysis patients' phosphate binder medication adherence.
    Sandlin K; Bennett PN; Ockerby C; Corradini AM
    J Ren Care; 2013 Mar; 39(1):12-8. PubMed ID: 23432740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' satisfaction with information about phosphate-binding medication.
    Parham R; Riley S; Hutchinson A; Horne R
    J Ren Care; 2009 Mar; 35 Suppl 1():86-93. PubMed ID: 19222738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
    Shahbazian H; Zafar Mohtashami A; Ghorbani A; Abbaspour MR; Belladi Musavi SS; Hayati F; Lashkarara GR
    Nefrologia; 2011; 31(1):58-65. PubMed ID: 21270914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary glands: a new player in phosphorus metabolism.
    Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
    J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Should we consider the cost-effectiveness analysis to apply the recommendations for phosphate-binders administration?].
    Martín de Francisco AL
    Nefrologia; 2008; 28(2):129-34. PubMed ID: 18454700
    [No Abstract]   [Full Text] [Related]  

  • 19. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
    Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
    J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.